Biocomposites entered into a multi-year agreement with Zimmer Biomet to exclusively distribute genex Bone Graft Substitute with its new mixing system and delivery options in the U.S. orthopedic market.
genex is a biphasic composite that is formulated to balance osteoconductive scaffold strength and persistence in the body to support the optimal remodeling of bone architecture. As part of the new agreement, genex has been upgraded for the U.S market to include a new closed-mixing system, to shorten preparation time and extend working time. In addition, it includes a more comprehensive set of delivery options to allow a surgeon to inject, mold or prepare beads in accordance with their chosen technique.
genex Bone Graft Substitute's 50:50 biphasic composition of calcium sulfate and beta-tricalcium phosphate has a negatively charged surface chemistry that has demonstrated a favorable osteogenic bone growth response up to five times normal (positively charged) levels, in vitro. The proprietary recrystallization and purification production methods remove slow and non-absorbing compounds, such as hydroxyapatite, to ensure that it is completely absorbed and remodeled within 12 months.